Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality of life Conference call scheduled
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP ticker.
The condition causes loss of lung function, hospitalisations and death. COPD affects approximately 384 million people worldwide and is projected to be the third leading cause of death by 2030, according to the World Health Organization.Find out more
17 January 2020
13 January 2020